• 1. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 4. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 5. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Amphetamines and derivatives
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenethylamines Amphetamines and derivatives

Research Brief on 2-amino-3-(3-fluorophenyl)propan-1-ol (CAS: 35373-68-3): Recent Advances and Applications

The compound 2-amino-3-(3-fluorophenyl)propan-1-ol (CAS: 35373-68-3) has garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. Recent studies have explored its potential as a key intermediate in the synthesis of bioactive molecules, particularly in the context of central nervous system (CNS) disorders and metabolic diseases. This research brief aims to summarize the latest findings, methodologies, and implications associated with this compound, providing a comprehensive overview for professionals in the field.

One of the most notable advancements in the study of 2-amino-3-(3-fluorophenyl)propan-1-ol is its role in the synthesis of β-adrenergic receptor agonists and antagonists. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a precursor in the development of novel bronchodilators for asthma treatment. The researchers utilized a multi-step synthetic pathway, incorporating 35373-68-3 as a chiral building block, to achieve high enantiomeric purity and yield. The resulting compounds exhibited enhanced binding affinity to β2-adrenergic receptors, highlighting the compound's potential in respiratory therapeutics.

In addition to its applications in respiratory medicine, recent research has also investigated the neuropharmacological properties of 2-amino-3-(3-fluorophenyl)propan-1-ol. A study in Neuropharmacology (2024) explored its modulatory effects on dopamine and serotonin receptors, suggesting its utility in the treatment of psychiatric disorders such as depression and schizophrenia. The compound's fluorophenyl moiety was found to enhance blood-brain barrier permeability, a critical factor in CNS drug development. These findings underscore the importance of 35373-68-3 as a scaffold for designing next-generation psychotropic agents.

From a methodological perspective, advancements in synthetic chemistry have enabled more efficient and sustainable production of 2-amino-3-(3-fluorophenyl)propan-1-ol. A recent Green Chemistry publication (2024) detailed a catalytic asymmetric hydrogenation approach, reducing the reliance on hazardous reagents and minimizing waste generation. This environmentally friendly method not only improves the scalability of production but also aligns with the growing emphasis on green chemistry principles in pharmaceutical manufacturing.

In conclusion, the compound 2-amino-3-(3-fluorophenyl)propan-1-ol (CAS: 35373-68-3) continues to be a focal point of research in chemical biology and drug development. Its diverse applications, from respiratory therapeutics to neuropharmacology, coupled with advancements in synthetic methodologies, position it as a valuable asset in the quest for novel and effective treatments. Future research directions may include further exploration of its pharmacokinetic properties and potential combination therapies, paving the way for innovative clinical applications.

• 1260817-75-1(2-amino-3-(4-fluorophenyl)propan-1-ol hydrochloride)
• 938462-29-4((S)-2-Amino-3-(3-fluorophenyl)propan-1-ol)
• 64230-78-0(Benzenepropanol, b-amino-4-fluoro-)
• 2102410-90-0(2-Amino-3-(4-fluorophenyl)propan-1-OL hydrochloride)
• 200267-65-8((S)-2-amino-3-(4-fluorophenyl)propan-1-ol)
• 774243-59-3((R)-2-Amino-3-(3-fluorophenyl)propan-1-ol)
• 218450-18-1(2-amino-3-(3,4-difluorophenyl)propan-1-ol)
• 35373-69-4(2-amino-3-(4-fluorophenyl)propan-1-ol)
• 348619-91-0((R)-2-Amino-3-(4-fluorophenyl)propan-1-ol)
• 64230-77-9(Benzenepropanol, b-amino-3-fluoro-, hydrochloride(1:1))